

# Immunotoxicology Specialty Section Newsletter



## 2006 - 2007 Executive Committee

### President

Dr. Mitchell D. Cohen

### Vice President

Dr. Stephen B. Pruet

### Vice President-Elect

Dr. Jeanine L. Bussiere

### Secretary-Treasurer

Dr. Helen V. Ratajczak

### Past President

Dr. Kenneth L. Hastings

### Senior Councilor

Dr. Gregory S. Ladics

### Councilor

Dr. Rod Dietert

### Post-Doc Representative

Dr. Jamie DeWitt

### Student Representative

Sheung Ng

The Immunotoxicology Specialty Section Newsletter is published 3 times/year (May, August and November). If you would like to share a book review, meeting report, interesting web site or any other item of interest with members of the Specialty Section, please send it to us by the middle of the month preceding the planned publication date. All comments on, or suggestions for, the newsletter are welcome.

Helen V. Ratajczak, Ph.D., Editor  
94C Miry Brook Road  
Danbury, CT 06810  
Tel. (203) 778-6826 Fax (203) 748-6512  
[hratajcz@comcast.net](mailto:hratajcz@comcast.net)

Stephen B. Pruet, Ph.D., Associate Editor  
Department of Cellular Biology and Anatomy  
LSU Health Sciences Center  
1501 Kings Highway  
Shreveport, LA 71130  
Tel. (318) 675-4386 Fax (318) 675-5889  
[spruet@lsuhsc.edu](mailto:spruet@lsuhsc.edu)

Typesetting provided by L. Peyton Myers, Ph.D.

## President's Message

*Mitch Cohen*

Here's hoping everyone had a nice Thanksgiving and that the same will continue on into the next slew of holidays in the coming weeks. During this interim period where everyone is sort of reachable, to be brief, there are only three items to report on this go-round.

First, I want to urge everyone to consider nominating a paper for Best Publication of the Year (see August '06 Newsletter for more info) and to encourage students and post-docs (PDs) to apply for their Best Presentations Awards. These have respective deadlines in January and very early February 2007. We have been kind of wobbly with respect to consistency with these two awards over the past few years, so let's try to assure all of them get awarded this coming annual meeting. Both Helen and Haley do yeopersons' work in gathering the titles of papers published by our SS members for each newsletter – so take advantage of these lists (found at back of each issue) to start to get a feel for a paper you think is deserving of our section's award when we meet in Charlotte.

Second, in this Newsletter you will find a joint report penned by Drs. Jean Regal and Kazu Nakamura on our section's ongoing and growing interactions with the Japanese Society of Immunotoxicology. Jean had the pleasure of being an invited speaker at the recent JSIT annual meeting in Kurashiki; plans are already underway to select one of our fellow IMTOX members to speak at the 2007 meeting in Kobe. In addition, having finally worked out the logistical kinks on our end, we are in the process of helping to bring the first JSIT-designated member to our national meeting (in Seattle 2008) where they too will have the honor of speaking in one of our scientific forums.

Our SS has been lauded by SOT National for this outreach/collaboration program and we would like to grow it some. As noted in the past, it would be great if we would be able to establish similar links with colleagues/societies in Korea, China, and India. In addition, an idea has been floated about creating a mechanism by which we might be able to bring a grad student/PD from Europe to each annual meeting. So long as our finances remain strong and our SS continues to receive the support of National SOT (both moral and, more importantly, in-part financial), I believe these goals are likely to be achieved in Steve Pruet's term as SS President. As always, the Executive Committee looks forward to your suggestions on how to enhance our links with other societies and immunotoxicologists from around the world.

Japanese Society  
of Immunotoxicology

Report of 13th Ann. Mtg. ... See [page 4](#)  
ITox Collaborations ..... See [page 5](#)

Third and last, as this is the end of 2006, it also means it is time to re-up for SOT for 2007. **More critically, it is time to re-up for the IMTOX Specialty Section!!!** I am currently working with Rosibel at National HQ to have **IMTOX SS pre-checked forms created** for each category of member (Full/Associate-US; Full/Associate-International; Student-US; Student-International; Retired-US; Retired-International) that can then be faxed to HQ with the dues payment. This effort was undertaken so that we don't run into the annual problem of members paying their dues and then falling off our membership roles due to the box not getting checked off (or later not recognized as checked-off) for whatever reason. Of course, the original on-line version from SOT (<http://www.toxicology.org>, then scroll down to membership bar under Inside SOT section) will always be available to use if you prefer that method to the fax version.

**Please don't forget to pay your dues and click/check the IMTOX SS box!!!**

The monies we receive back from National go a long ways in helping to support our yearly awards, our annual shindig (cheese included), our grad student/PD-related events at the annual meeting, our interactions with national and international organizations, and any future endeavors that our SS might want to undertake.

Have a happy holiday season!

## Post-doctoral Representative Report



*Submitted by Jamie DeWitt*

Greetings post-docs! If you are reading this article, then you are an active member (or are at least actively interested in) the Immunotoxicology Specialty Section. Good for you! You have taken a step toward becoming a full participant in the toxicological community. I am not trying to be patronizing, just realistic. As graduate students, myriad opportunities for organizational involvement seemed to fall in our laps. As post-docs, it doesn't seem quite that easy. We've passed the test and that now we're grown-up scientists, it almost seems like the nurturing organizational support we had as graduate students has disappeared. Right? Nope. Wrong. We have loads of organizational support and we don't have to look far to find it. Post-doctoral representation within the SOT has been formalized with the creation of the Post-Doctoral Assembly (PDA). One of the PDA's goals is to create a network of post-docs within SOT, through the existing organizational structure. This means post-doctoral representation




in specialty sections, regional chapters, and special interest groups. Check out the latest PDA newsletter at

[http://www.toxicology.org/AI/SPD/SOT\\_PDA\\_NLFall2006.pdf](http://www.toxicology.org/AI/SPD/SOT_PDA_NLFall2006.pdf).

Want to broaden your network? Have your advisor nominate you to become the next post-doctoral representative of the ISS. All your advisor has to do is send a letter of recommendation to the ISS president that includes verification that he or she can fund your travel to SOT for the next two years. Your term would run from March 2007-March 2009 and you would serve as THE post-doctoral voice on the ISS. Think about it. You can't expand your professional network by hiding in the lab.

If you have any questions about post-doctoral representation in the ISS, please do not hesitate to contact me at [dewitt.jamie@epa.gov](mailto:dewitt.jamie@epa.gov). See you in Charlotte!



For further SOT Membership Renewal Information:

<http://www.toxicology.org/AI/MI/mem-RenewalSteps.asp>

# Program Committee Report



Submitted by  
*Jeanine Bussiere*

## **NOTICE: DEADLINE FOR SUBMISSION FOR ISS PROGRAMS HAS BEEN EXTENDED TO JANUARY 2, 2007!!**

Please be thinking about submitting a program for the 2008 SOT meeting in Seattle, WA. Our Specialty Section has always put forth good program ideas, had an excellent record of acceptance for programs submitted to the SOT National Committee, and had very well-attended sessions at the annual meeting. We especially are seeking submissions from members who have not previously chaired and from new investigators, post-docs, and students. That means starting now to flesh out an idea of yours that would update an area of interest/bring forward a new concept. A complete guide to programs sponsored/co-sponsored by IMTOX since 2001 is now available (see Aug 2005 Newsletter). This is useful as it can provide some guidance as to what subject matters really haven't had their day in the light at all, have not been touched upon or updated in a bit, or have been done to a near-numbing level. During the process of formulating your idea for a session at the 2008 Seattle meeting, it is important to think about: the objective and rationale for the session; the timeliness of, or controversy around, the topic; who would be your co-chair; who would be interesting appropriate speakers in your program; and, the format - emphasis of/requirement for each are:

### **Continuing Education Courses**

- ◆ Basic courses are intended to familiarize investigators with a defined knowledge base or to assist them in developing, implementing or learning techniques or approaches
- ◆ Advanced courses are intended to be of interest for those already working in the field

### **Symposia**

Cutting-edge science, new areas for toxicologists, new concepts or approaches, new data

- ◆ 3 hours or less
- ◆ Chairperson and 4-5 speakers (30 minutes per speaker)
- ◆ Summary of symposium by last speaker

### **Workshop**

Topics requiring intensive study and discussion

- ◆ 3 hours or less
- ◆ One to five speakers
- ◆ Informal, interactive presentations
- ◆ Emphasis on discussion

### **Roundtable**

Controversial subject matter

- ◆ 1.5 hours
- ◆ Moderator and 2-4 speakers
- ◆ Moderator presents overview
- ◆ Each speaker makes a 3-5 minute statement (Moderator coordinates the comment)
- ◆ Balance of time for questions and discussion

Keep in mind that your program should be attractive to a broad enough segment of meeting attendees and not just to your fellow IMTOX members (i.e., so it could at-

tract co-sponsoring by other Specialty Sections); likelihood of approval by the National Program Committee is usually higher for co-sponsored sessions. Lastly, and importantly, while a proposal dealing with the underlying biology and mechanism(s) of effect of a toxicant/class of agents would undoubtedly be of great interest to many meeting attendees, the National Committee will not likely approve it unless the focus of the session remains anchored in the toxicology of the agent(s). Please feel free to contact me or any one of the committee members below when you have your idea(s) ready to submit or if you have any questions or complaints.



## 2006-2007 Program Committee

Jeanine Bussiere (Chair)  
Tony Arulanandam  
Robert Caldwell  
Girish Ramdas Chaudari  
Jamie DeWitt  
Dori Germolec  
Andrij Holian  
M. Firoze Khan  
Ian Kimber  
Greg Ladics  
Lynne LeSauteur  
Tina Satterwhite  
Allen Silverstone  
Petia Simeonova  
Mike Woolhiser

---

Kathy Sarlo (mandated/carryover)  
Steve Pruett (mandated/carryover)  
Mitch Cohen (mandated/carryover)

## REPORT FROM THE 13<sup>th</sup> ANNUAL MEETING OF THE JAPANESE SOCIETY OF IMMUNOTOXICOL- OGY

Kurashiki, Japan  
SEPTEMBER 14-15,  
2006

*Submitted by Jean Regal and  
Kazuichi Nakamura*

The Japanese Society of Immunotoxicology is comprised of approximately 300 scientists working in academia, industry, and government agencies. The 13<sup>th</sup> Annual Meeting of the Japanese Society of Immunotoxicology (JSIT) was held on September 14-15, 2006 at Artistic and Literary Hall in the old city of Kurashiki. The setting was beautiful and included old merchant warehouses along a tree-lined river in the Okayama prefecture in western Japan. The theme of the meeting was “Immunotoxicology and Pathophysiological Constitution.” The meeting opened with a keynote lecture on the effects of asbestos on immunocompetent cells by Dr. Takemi Otsuki, Professor at Kawasaki Medical School and the President of the 13<sup>th</sup> Annual Meeting. Two special lectures the first day included a presentation by Dr. Lee Newman, Professor of Medicine, University of Colorado, entitled “Immunotoxicology of Beryllium Lung Disease” and by Dr. Jean Regal, University of Minnesota, entitled “Models and Mechanisms of Chemical Respiratory Allergy.” In addition, the first day was highlighted by two invited lectures by Japanese experts: Dr. Hiroyuki Takano presented a talk on “Inflammation and

Environmental Factors” and Professor Kou Sakabe focused on “Sick House Syndrome”. A symposium on the second day examined “Fibrous and Particulate Substances and Immunotoxicology”. The afternoon workshop focused on “ICH S8 Guideline for Immunotoxicity Studies for Human Pharmaceuticals”. In addition to the lectures, many excellent oral and poster presentations covered a broad spectrum of immunotoxicology. The participants welcomed the announcement of Kobe, Japan as the site for the 14<sup>th</sup> Annual Meeting of JSIT in September, 2007.



*Jean Regal at 13<sup>th</sup> Annual  
Meeting of JSIT*

As part of the Annual Meeting, the Executive Board of the Japanese Society of Immunotoxicology met and discussed ways to increase collaboration with the SOT Immunotoxicology Specialty Section (ISS). Dr. Nakamura will regularly distribute the ISS Newsletter to members of JSIT. In addition, English summaries of presentations and messages from foreign speakers invited to the 13<sup>th</sup> Annual JSIT Meeting will be included in the JSIT Newsletter for circulation within the ISS.

A wonderful dinner reception was held the evening of September 15 at Kurashiki Tivoli Park, a theme park close by the meeting site. As part of the reception, Dr. Takemi Otsuki, the pianist and composer, premiered his “Song for the 13<sup>th</sup> JSIT” calling for us to “talk together to develop the strategies to overcome the impairments from immunotoxicity.” Dr. Otsuki’s original lyrics and music were a definite ‘top 10’ as he sang and played the piano accompanied by violins. The Japanese hospitality was exceptional and the reception provided wonderful opportunities for discussion after a high quality scientific meeting.

*Dr. Otsuki at the  
piano singing his  
“Song for the 13<sup>th</sup>  
JSIT”*



## AN INTERNATIONAL IMMUNOTOXICOLOGY NETWORK: INCREASED COLLABORATIONS BETWEEN THE JSIT AND SOT IMMUNOTOXICOLOGY SPECIALTY SECTION

*Submitted by Jean Regal*

As we heard from Dr. Kazuichi Nakamura at our Specialty Section reception in San Diego, the Japanese Society of Immunotoxicology (JSIT) has consistently made efforts to invite speakers from abroad to their yearly meetings. As a representative of the Immunotoxicology Specialty Section, I had the honor this year of presenting a lecture at the JSIT meeting in Kurashiki, Japan, with Dr. Takemi Otsuki as the president. This allowed me first-hand to see the


depth and breadth of high quality immunotoxicology research going on in Japan. Thanks to the efforts of Mitch Cohen and Kazuichi Nakamura, my trip was sponsored by JSIT, Shionogi & Co., Ltd., the Journal of Immunotoxicology and the SOT Immunotoxicology Specialty Section. In addition to presenting at the JSIT meeting, I was invited to present a seminar at Shionogi Laboratories in Osaka. In Kurashiki, I met with members of the JSIT Executive Board and discussed continuing scientific exchange between JSIT and the SOT Immunotoxicology Specialty Section. I have to especially thank Dr. Kazuichi Nakamura for making this scientific exchange possible. He has been a continuous driving force in increasing the exchange of science between the SOT Immunotoxicology Specialty Section and JSIT. In addition, he is a dynamite tour director and made sure that I sampled delicious Japanese foods while touring impressive Japanese gardens, castles and temples in Okayama, Himeji and Kyoto.



*Members of JSIT Executive Board and Jean Regal at the 13<sup>th</sup> Annual Meeting of JSIT. Left to right: Drs. Keiko Nohara, Jean Regal and Kazuichi Nakamura.*

## IMMUNOTOXICOLOGY

The Immunotoxicology Specialty Section is a branch of the Society of Toxicology whose members include scientists with training in immunology, toxicology and risk assessment. Our purpose is to promote immunotoxicology as a discipline by: (1) increasing our understanding of the impact that xenobiotics have on the immune system (2) advocating research into the mechanisms of immunomodulation, and (3) encourage the development of new methods and techniques to improve risk assessment. At the national meeting, the Section sponsors symposia, continuing education courses, workshops and roundtable discussions. Annual meetings are held at the national meeting to discuss specialty section business and program topics for the following year. Pre- and postdoctoral students are encouraged to participate in the scientific program at the Annual Meeting by presentation of an award for best poster session in the field of immunotoxicology. Student input into the Section is also encouraged, and facilitated by an appointed Student Representative that attends Section Officer's meetings as a full voting member.



## Summerschool in Immunotoxicology Annual PhD Award

In order to enhance its long-standing commitment to the promotion of immunotoxicology, the nonprofit association “Summerschool in Immunotoxicology” is pleased to announce that it will present an Annual PhD Award starting from 2007, in recognition of outstanding student candidates for their contribution to the field of immunotoxicology.

In addition to the 1,000 € prize, the 2007 recipient will be the guest (including registration, accommodation and travel expenses) of the 16th Summerschool in Immunotoxicology to be held in October in Lyon (France), and will be invited to give a 15-min oral presentation summarizing his (her) most significant results.

Any student having obtained a PhD degree (or recognized equivalent) during the 12 months prior to the application deadline for original work strictly in the area of immunotoxicology is eligible. However, the submitted PhD thesis should be either in English or French, unless an English or French summary is provided together with the applicant’s original papers strictly derived from his or her PhD work.

Applications, including the candidate’s CV and PhD thesis in final form should be submitted to the Summerschool President Prof. Jacques Descotes:

E-mail: [jacques-georges.descotes@chu-lyon.fr](mailto:jacques-georges.descotes@chu-lyon.fr)

Post mail : Centre Antipoison, 162 av. Lacassagne, 69424 Lyon cedex 03, France.

**The next deadline for application is 1st June 2007.**

# CALL FOR PAPERS



## Please submit papers to:

Mitchell D. Cohen, PhD  
Editor-in-Chief, Journal of Immunotoxicology  
New York University School of Medicine  
Nelson Institute School of Medicine  
57 Old Forge Road, Tuxedo, NY 10987 USA  
cohenm@env.med.nyu.edu

## Associate Editors

Donald E. Gardner, PhD/ATS Fellow, Inhalation Toxicology Associates

Kenneth L. Hastings, Dr.PH./DABT, Center for Drug Evaluation and Research, U.S. Food and Drug Administration

Robert V. House, PhD, Dynport Vaccine Company LLC

Robert W. Luebke, PhD, National Health and Environmental Effects Research Laboratory, U.S. Environmental Protection Agency

Jean F. Regal, PhD, Department of Pharmacology, University of Minnesota

Kazuichi Nakamura, DVM, PhD, Shionogi & Co., Ltd., Japan

Joseph G. Vos, DVM, PhD, National Institute of Public Health and the Environment (RIVM), the Netherlands

**Access your FREE online sample copy today!**

**Please visit:**

**<http://www.tandf.co.uk/journals/titles/1547691X.asp>**

The *Journal of Immunotoxicology* is a peer-reviewed journal that provides a needed singular forum for the international community of immunotoxicologists, immunologists, and toxicologists working in academia, government, consulting, and industry to both publish their original research and be made aware of the research findings of their colleagues in a timely manner. Research from many subdisciplines are presented in the journal, including the areas of molecular, developmental, pulmonary, regulatory, nutritional, mechanistic, wildlife, and environmental immunotoxicology, immunology, and toxicology. Original research articles as well as timely comprehensive reviews are published.

**Here is a sampling of articles that have appeared in recent issues:**

**New Developments in the Assessment of Developmental Immunotoxicology**, Rodney R. Dietert

**Preclinical Immunogenicity Testing for Recombinant Therapeutic Proteins**, Holly W. Smith and Daniel Wierda

**Altered Splenocyte Function in Aged C57BL/6 Mice Prenatally Exposed to Diethylstilbestrol**, Jillian B. Fenaux, Robert M. Gogal, David Lindsay, Carrie Hardy, Daniel L. Ward, Geoffrey Saunders, and S. Ansar Ahmed

**Organic Chemicals Adsorbed onto Diesel Exhaust Particles Directly Alter the Differentiation of Fetal Thymocytes Through Arylhydrocarbon Receptor but Not Oxidative Stress Responses**, Tomohiro Ito, Haruko Nagai, Tien-Min Lin, Richard E. Peterson, Chiharu Tohyama, Takahiro Kobayashi, and Keiko Nohara

**The Relationship Between Noncoplanar PCB-Induced Immunotoxicity and Hepatic CYP1A Induction in a Fish Model**, Jessica E. Duffy and Judith T. Zelikoff

## Journal of Immunotoxicology

Quarterly, Volume 3 (2006)

Print ISSN: 1547-691X Online ISSN: 1547-6901

Institutional print & online subscription at US\$529/£321\*

Personal print subscription at US\$188/£114

Special SOT member print subscription at US\$85/£52\*

\*Institutional and SOT subscriptions include free online access

To subscribe or for more information, contact:

**Taylor & Francis**

Attn: Mary Drabot

325 Chestnut Street

Philadelphia, PA 19106

Tel: (215) 625-8900 ext. 228

Fax: (215) 625-2940

E-mail: [mary.drabot@taylorandfrancis.com](mailto:mary.drabot@taylorandfrancis.com)

**informa**  
healthcare



### **Novartis Group Head Investigative Immunotoxicology at Novartis Pharma AG Basel (Switzerland)** **(Job ID 19531BR)**

Investigative Immunotoxicology is part of the larger Novartis Investigative Toxicology unit, which aims at studying toxicological mechanisms in a multidisciplinary integrated manner. The Group Head Investigative Immunotoxicology - located in Basel, Switzerland - supervises and coordinates immunological and immunotoxicological approaches and methodologies in order to support development of biotechnology-derived (e.g. monoclonal antibodies) as well as low molecular weight drugs. The Group Head leads a team aimed at exploring the role and contribution of the immune system in various drug-induced target organ toxicities (e.g. liver, skin, hematopoietic system) and interacts closely with colleagues from Investigative Toxicology as well as Exploratory Development and Research in Novartis. She/he is expected to integrate and communicate results leading to improved hazard identification models and risk assessments in drug development programs, and acts as the immunotoxicological expert in cross-functional, multi-disciplinary teams.

University degree in life sciences. PhD in Immunology or related fields desirable. Strong experience in establishing in vivo and in vitro models is essential. Leads a team in her/his current position. Fluency in English (written and spoken) is a must. Skills: Ability to lead a team, flexible and able to work in a team, excellent communication skills, independent working style, ability to plan and organize effectively, accurate working style, willingness to take over additional responsibilities.

Michael Kammüller, PhD  
Head Predictive Safety Models  
Safety Profiling & Assessment  
Novartis Pharma AG  
CH-4132 Muttenz  
Switzerland  
Tel. +41 61 324 12 73

---

---

### **Research Associate (Postdoctoral) in Immunotoxicology**

Seek a hard working and creative postdoctoral trainee for a project investigating the mechanisms by which polycyclic aromatic hydrocarbons adversely affect hematopoiesis. Candidates should have a Ph.D. in toxicology, immunology, cell biology or some other relevant biological science. Experience working with laboratory animals and tissue culture are important, as are contemporary skills in molecular biology. Accepted candidate will be encouraged to become involved in the Molecular and Environmental Toxicology Center at UW-Madison. Competitive stipend and benefits will be offered.

If interested, please send CV, brief statement of interest, and the names and contact information for three references to: Dr. Chuck Czuprynski, Dept. Pathobiological Sciences, 2015 Linden Drive, Madison, WI 53706. Phone and fax 608 262 8102 E-mail: [czuprync@svm.vetmed.wisc.edu](mailto:czuprync@svm.vetmed.wisc.edu) . Electronic applications are welcome.



### Flow Cytometry

#### Req ID# 1959

Covance Inc. is a stable, growing company in **Madison, WI**, where you can enjoy a great quality of life in a family-oriented environment. As one of the world's largest and most comprehensive drug development services companies, with annual revenues greater than \$1 billion, Covance leads advancements through science, targeted service and solution shaping for the most innovative global pharmaceutical and biotech companies.

Due to the expansion of our Madison, WI facility we have an exciting opportunity for you! In this position you will analyze samples in compliance with appropriate SOPs, GLPs and regulatory guidelines and validate new instrumentation and assays. You will evaluate instrument performance data; perform instrument set-up; perform quality control for all laboratory analyzers and proficiency testing as required. You will also train other staff on immunotoxicology assays.

To qualify, you must have a Bachelor's degree and 5 years of research laboratory experience, that includes flow cytometry experience and immunology testing techniques. Advanced flow cytometry training preferred.

**Covance offers relocation assistance!** Madison has a vibrant economy with plentiful jobs, superb health care, and a low crime rate. Due to the University of WI, Wisconsin's state government and Madison's lakes, its residents enjoy many nationally recognized festivals and leisure activities. In the past decade, Madison has placed in the top ranks among US cities in many categories including the Best City in America, Best Place for Business, most "Kid Friendly" cities and Best Cities for Women.

An additional benefit of living in this area is that Chicago is only 2 hours away by car and Milwaukee only an hour and a half. At the same time, a short half hour drive can put you well into open space and wildlife. Madison's residents have come to appreciate that this area holds something of interest for nearly everyone.

Why Wait? Apply Online to req #1959 today. [www.covance.com/careers](http://www.covance.com/careers)

Compiled by Haley Neff-LaFord.

**ANYTIME you have a new publication to report, please sent it to the new coordinator, Haley Neff-LaFord: [hneff@u.washington.edu](mailto:hneff@u.washington.edu).**

### Asthma, Allergy & Hypersensitivity

Betts CJ, Dearman RJ, Heylings JR, Kimber I and Basketter DA. Skin sensitization potency of methyl methacrylate in the local lymph node assay: comparisons with guinea-pig data and human experience. *Contact Derm* 55:140-147, 2006.

Pongratz G, McAlees JW, Conrad DH, Erbe RS, Haas KM and Sanders VM. The level of IgE produced by a B cell is regulated by norepinephrine in a p38 MAPK- and CD23-dependent manner. *J Immunol* 177:2926-2938, 2006.

### Effects: Compounds

Duffy JE and Zelikoff JT. The relationship between noncoplanar PCB-induced immunotoxicity and hepatic CYP1A induction in a fish model. *J Immunotox* 3:39-47, 2006.

Luongo D, Severino L, Bergamo P, De Luna R, Lucisano A and Rossi M. Interactive effects of fumonisin B1 and  $\alpha$ -zearalenol on proliferation and cytokine expression in Jurkat T cells. *Toxicol in vitro* 20:1403-1410, 2006.

Mainwaring G, Lim FL, Antrobus K, Swain C, Clapp M, Kimber I, Orphanides G and Moggs JG. Identification of early molecular pathways affected by paraquat in rat lung. *Toxicology* 225:157-172, 2006.

Nohara K, Ao K, Miyamoto Y, Ito T, Suzuki T, Toyoshiba H and Tohyama C. Comparison of the 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-induced CYP1A1 gene expression profile in lymphocytes from mice, rats, and humans: Most potent induction in humans. *Toxicology* 225:204-213, 2006.

### Models & Methods

Cockshott A, Evans P, Ryan CA, Gerberick GF, Betts CJ, Dearman RJ, Kimber I and Basketter DA. The local lymph node assay in practice: a current regulatory perspective. *Hum Exp Toxicol* 25:387-394, 2006.

Jowsey IJ, Basketter DA, Westmoreland C and Kimber I. A future approach to measuring relative skin sensitising potency: a proposal. *J Appl Toxicol* 26:341-350, 2006.

### General Immunotoxicology

Baken KA, Ezendam J, Gremmer E, De Klerk A, Pennings JLA, Matthee B, Peijnenburg ACM and Van Loveren H. Evaluation of immunomodulation by *Lactobacillus casei* Shirota: immune function, autoimmunity, and gene expression. *Int J Food Microbiol* 112:8-18, 2006.

Kin N and Sanders VM. CD86 stimulation on a B cell activates the PI3K/Akt and PLCg2/PKCa/b signaling pathways. *J Immunol* 176:6727-6735, 2006.

Luebke RW, Chen DH, Dietert R, Yung Y and Luster MI. Immune system maturity and sensitivity to chemical exposure. *J Toxicol & Environ Hlth Part A* 1-15, 2006.

Ng SP, Steinetz BG, Lasano SG and Zelikoff JT. Hormonal changes accompanying cigarette smoke-induced preterm births in a mouse model. *Exp Biol Med* 231:1403-1409, 2006.

Roggen EL, Kristensen Soni N and Verheyen GR. Respiratory immunotoxicity: An in vitro assessment. *Toxicol in vitro* 20:1249-1264, 2006.

Steerenberg PA, Daamen F, Wessendorp E and Van Loveren H. No adaptation to UV-induced immunosuppression and DNA damage following exposure of mice to chronic UV-exposure. *J Photochem Photobiol B* 84:28-37, 2006.

Vorderstrasse BA and Lawrence BP. Protection against lethal challenge with *Streptococcus pneumoniae* is conferred by aryl hydrocarbon receptor activation but is not associated with an enhanced inflammatory response. *Infect Immun* 74:5679-5686, 2006.

## Developmental Immunotoxicology

Dietert R. Developmental immunotoxicity testing and protection of children's health. *PLoS Medicine* 3: 1216-1217, 2006.

Ng SP, Silverstone AE, Lai ZW and Zelikoff JT. Effects of prenatal exposure to cigarette smoke on offspring tumor susceptibility and associated immune mechanisms. *Toxicol Sci* 89:135-144, 2006.

Prater R, Johnson VJ, Germolec DR, Luster MI and Holladay SD. Maternal treatment of high dose CpG ODN during gestation alters fetal craniofacial and distal limb development in the C57BL/6 mouse model. *Vaccine* 24:263-271, 2006.

Steinetz BG, Gordon T, Lasano S, Horton L, Ng SP, Zelikoff JT, Nadas A and Bosland MC. The parity-related protection against breast cancer is compromised by cigarette smoke during rat pregnancy: observations on tumorigenesis and immunological defenses of the neonate. *Carcinogenesis* 27:1146-1152, 2006.

Stuckey R, Aldridge T, Lim FL, Moore DJ, Tinwell H, Doherty N, Davies R, Smith AG, Kimber I, Ashby J, Orphanides G and Moggs JG. Induction of iron homeostasis genes during estrogen-induced uterine growth and differentiation. *Mol Cell Endocrinol* 253:22-29, 2006.

## Neuroimmunology

DeBoy CA, Byram SC, Serpe CJ, Wisuri D, \*Sanders VM and \*Jones KJ (\*=equivalent contribution). CD4+CD25+regulatory T cells and CD1-restricted NKT cells do not mediate facial motoneuron survival after axotomy. *J Neuroimmunol* 176:34-38, 2006.

DeBoy CA, Xin J, Byram SC, Serpe CJ, \*Sanders VM and \*Jones KJ (\*=equivalent contribution). Immune-mediated neuroprotection of axotomized mouse facial motoneurons is dependent on the IL-4/STAT6 signaling pathway in CD4+ T cells. *Exp Neurol* 201:212-224, 2006.

Kin N and Sanders VM. It takes nerve to tell T and B cells what to do. *J Leuk Biol* 79:1093-1104, 2006.

Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI and O'Callaghan P. Microglial activation and MPTP-induced neurotoxicity: Region-specific role for TNF $\alpha$ . *Neuroscience* 20:670-682, 2006

Sriram K, Matheson JM, Benkovic SA, Miller DB, Luster MI and O'Callaghan JP. Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF $\alpha$ . *FASEB Journal* 20:670-682, 2006.

Yucesoy B, Peila R, White LR, Wu KM, Johnson VJ, Kashon ML, Luster MI and Launer LJ. Association of interleukin-1 gene polymorphisms with late-onset Alzheimer's disease and vascular dementia in a community based sample: the HAAS. *Neurobiol of Aging* 27: 211-217, 2006.

#### Reviews and Book Chapters:

Blanciforti L and Luster MI. Establishing estimates for social and economic impacts of immunotoxic agents. *Human & Ecological Risk Assessment* 12:1-16, 2006.

Burns-Naas LA, Dearman RJ, Germolec D, Kaminski NE, Kimber I, Ladics GS, Luebke R, Pfau J and Pruett SB. Invited Review: "Omic" technologies and the immune system. *Toxicol Mech Methods* 16:101-119, 2006.

Dean JH, House RE, and Luster MI. Immunotoxicology: Effects of, and response to, drugs and chemicals. In *Principles and Methods of Toxicology*. Ed. A. W. Hayes 5th Edition, Raven Press, New York, (In press).

Ezendam J and Van Loveren H. Probiotics: Immunomodulation and evaluation of safety and efficacy. *Nutr Rev* 64:1-14, 2006.

Johnson VJ and Luster MI. Animal models of occupational asthma: Tools for understanding disease pathogenesis. In *Asthma and the Workplace* Eds. I.L. Bernstein, M. Chan-Yeung, J-L Malo, D. I. Bernstein 3rd Edition, Taylor and Francis, New York/London, pp141-160, 2006.

Pruett SB, Holladay SD, Prater MR, Yucesoy B and Luster MI. The promise of genomics and proteomics in immunotoxicology: In: *Immunotoxicology and Immunopharmacology*, 3rd Edition, (in press).

Yucesoy B, Johnson VJ, Kashon ML and Luster MI. Cytokine polymorphisms and relationship to disease. In *Cytokines in Human Health: Immunotoxicology, Pathology and Therapeutic Applications*. Eds. R. House and J Descotes Humana Press Inc., Totowa, NJ Chapter 7 pp. 111-130 2006.

Yucesoy B and Luster MI. Pulmonary fibrosis. In: *Cytokine gene polymorphisms in multifactorial disorders*. CRC, pp351 -362 (in press).